Article Text

Download PDFPDF
Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results
  1. Filiz Cebeci1,
  2. İlkay Kartal2
  1. 1 Department of Dermatology, Istanbul Medeniyet University, Istanbul, Turkey
  2. 2 Department of Endocrinology, Istanbul Medeniyet University, Istanbul, Turkey
  1. Correspondence to Professor Filiz Cebeci, Dermatology, Istanbul Medeniyet University, Istanbul 34720, Turkey; cebecifiliz{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Due to the newness of the virus, side effects of vaccines specific to SARS-CoV-2 are not yet known. CoronaVac, a purified inactivated SARS-CoV-2 vaccine developed by Sinovac Biotech (Beijing, China), has been shown to induce SARS-CoV-2-specific neutralising antibodies in mice, rats, non-human primates and in macaques.1 CoronaVac was shown to be well tolerated and did not cause dose-related safety concerns in phase 1 and 2 clinical studies involving healthy individuals aged 18–59 years2 and those aged 60 years and older.3 The most common symptom was injection site pain, and hypersensitivity reactions were the least reported side effects.2 We do not know the phase 3 efficacy and side effect results of CoronaVac, although vaccination has started. Turkey has decided on the CoronaVac within the vaccine market and is currently continuing the vaccination of elderly people following health workers. Here we share up-to-date data on an elderly person who developed post-vaccination side effects in the form of a petechial rash.

An 82-year-old woman presented with weakness, burning in the legs and a rash. A diffuse petechial rash was observed on both lower extremities during dermatological examination (figure 1A,B). It was learned that she had been vaccinated with CoronaVac 1 day before the petechial …

View Full Text


  • Contributors FC is the primary physician of the patient discussed in this paper and supervised the process, created the idea, designed the process, reviewed the article, took part in patient care, data collection, literature review, writing and preparation of the manuscript. İK took part in the diagnosis and patient evaluation and reviewed the article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.